Ribavirin has been widely used for the treatment of HCV chronic hepatitis of non-immunocompromised patients and, lately, it has been used even in liver or kidney transplant patients. A 51 y.o. male with a 8-year history of well functioning renal transplant (creatinine 1.6 mg/dl) developed abiopsy-proven HCV-related chronic active hepatitis with marked cholestasis and histological findings of periportal bridging. After ribavirin treatment at a daily dosage of 600 mg p.o. a normalization of cholestatic indexes was detected with a negative PCR-RNA HCV. After 18 months of treatment no relevant side effects was detected and the renal function remained stable.
Campieri C., Moschella M.R., Perna C., Zanchelli F., Polifemo A.M., Morelli C., et al. (1998). A 18-months ribavirin treatment for cholestatic chronic HCV-related hepatitis in a kidney transplant patient. GIORNALE ITALIANO DI NEFROLOGIA, 15(5), 267-269.
A 18-months ribavirin treatment for cholestatic chronic HCV-related hepatitis in a kidney transplant patient
Manna C.;La Manna G.;Casanova S.;Stefoni S.;Bonomini V.
1998
Abstract
Ribavirin has been widely used for the treatment of HCV chronic hepatitis of non-immunocompromised patients and, lately, it has been used even in liver or kidney transplant patients. A 51 y.o. male with a 8-year history of well functioning renal transplant (creatinine 1.6 mg/dl) developed abiopsy-proven HCV-related chronic active hepatitis with marked cholestasis and histological findings of periportal bridging. After ribavirin treatment at a daily dosage of 600 mg p.o. a normalization of cholestatic indexes was detected with a negative PCR-RNA HCV. After 18 months of treatment no relevant side effects was detected and the renal function remained stable.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
